Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CONMED Corporation or Insulet Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CONMED Corporation and Insulet Corporation compare based on key financial metrics to determine which better meets your investment needs.

About CONMED Corporation and Insulet Corporation

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Latest Health Care Equipment & Supplies and CONMED Corporation, Insulet Corporation Stock News

As of December 11, 2025, CONMED Corporation had a $1.2 billion market capitalization, compared to the Health Care Equipment & Supplies median of $315.2 million. CONMED Corporation’s stock is down 41.8% in 2025, down 9.9% in the previous five trading days and down 46.65% in the past year.

Currently, CONMED Corporation’s price-earnings ratio is 19.4. CONMED Corporation’s trailing 12-month revenue is $1.3 billion with a 4.8% net profit margin. Year-over-year quarterly sales growth most recently was 6.7%. Analysts expect adjusted earnings to reach $4.501 per share for the current fiscal year. CONMED Corporation does not currently pay a dividend.

As of December 11, 2025, Insulet Corporation had a $20.7 billion market cap, putting it in the 87th percentile of all stocks. Insulet Corporation’s stock is up 12.7% in 2025, down 6.9% in the previous five trading days and up 10.96% in the past year.

Currently, Insulet Corporation’s price-earnings ratio is 85.2. Insulet Corporation’s trailing 12-month revenue is $2.5 billion with a 9.8% net profit margin. Year-over-year quarterly sales growth most recently was 29.9%. Analysts expect adjusted earnings to reach $4.892 per share for the current fiscal year. Insulet Corporation does not currently pay a dividend.

How We Compare CONMED Corporation and Insulet Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CONMED Corporation and Insulet Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CONMED Corporation and Insulet Corporation Stock Value Grades

Company	Ticker	Value
CONMED Corporation	CNMD	B
Insulet Corporation	PODD	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

CONMED Corporation has a Value Score of 68, which is Value. Insulet Corporation has a Value Score of 7, which is Ultra Expensive.

The Value Stock Winner: CONMED Corporation

As you can clearly see from the Value Grade breakdown above, CONMED Corporation is considered to have better value than Insulet Corporation. For investors who focus solely on a company’s valuation, CONMED Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

CONMED Corporation and Insulet Corporation’s Momentum Grades

Company	Ticker	Momentum
CONMED Corporation	CNMD	F
Insulet Corporation	PODD	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

CONMED Corporation has a Momentum Score of 11, which is Very Weak. Insulet Corporation has a Momentum Score of 40, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither CONMED Corporation or Insulet Corporation has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CONMED Corporation or Insulet Corporation is the better investment when it comes to momentum.

CONMED Corporation and Insulet Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
CONMED Corporation	CNMD	C
Insulet Corporation	PODD	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

CONMED Corporation has a Earnings Estimate Score of 57, which is Neutral. Insulet Corporation has a Earnings Estimate Score of 68, which is Positive.

The Earnings Estimate Revisions Grade Winner: Insulet Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Insulet Corporation has a better Earnings Estimate Revisions Grade than CONMED Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Insulet Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other CONMED Corporation and Insulet Corporation Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CONMED Corporation and Insulet Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CONMED Corporation or Insulet Corporation Stock?

Overall, CONMED Corporation stock has a Value Score of 68, Momentum Score of 11 and Estimate Revisions Score of 57.

Insulet Corporation stock has a Value Score of 7, Momentum Score of 40 and Estimate Revisions Score of 68.

Comparing CONMED Corporation and Insulet Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.